Combining Molecularly Targeted Agents: Is More Always Better?
暂无分享,去创建一个
Raghav Sundar | Nicola Valeri | Kevin J Harrington | Timothy A Yap | K. Harrington | T. Yap | N. Valeri | R. Sundar
[1] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[2] Hans Clevers,et al. Modeling Development and Disease with Organoids , 2016, Cell.
[3] U. Banerji,et al. Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic? , 2015, Clinical Cancer Research.
[4] Keunchil Park,et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Jänne,et al. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.
[6] Roman Rouzier,et al. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials , 2015, Journal of the National Cancer Institute.
[7] G. Scagliotti,et al. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] T. Yap,et al. Development of therapeutic combinations targeting major cancer signaling pathways. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Lovly,et al. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade , 2015, Clinical Cancer Research.
[10] J. Clohessy,et al. Mouse hospital and co-clinical trial project—from bench to bedside , 2015, Nature Reviews Clinical Oncology.
[11] M. Hidalgo,et al. A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors , 2016, Clinical Cancer Research.
[12] S. Ou,et al. Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era? , 2015, Drug design, development and therapy.